⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17560464 | 0.97 | — | — | |
| SCHEMBL5095124 | 0.81 | — | — | |
| SCHEMBL38658649 | 0.81 | — | — | |
| SCHEMBL5095130 | 0.81 | — | — | |
| SCHEMBL13572453 | 0.80 | — | — | |
| SCHEMBL207706 | 0.80 | — | — | |
| SCHEMBL17180333 | 0.80 | — | — | |
| SCHEMBL19015231 | 0.76 | — | — | |
| SCHEMBL2290317 | 0.73 | — | — | |
| SCHEMBL18050089 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116648250-B | Novel quinazoline derivatives as SOS1 inhibitors and uses thereof | 韩美药品株式会社 | 2025-06-13 | — | — | CN | claimed |
| CN-114761404-B | Substituted bicyclic heteroaryl compounds | 百时美施贵宝公司 | 2025-02-21 | — | — | CN | claimed |
| US-20240197888-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | 2024-06-20 | — | — | US | claimed |
| US-20240174643-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. (US) | 2024-05-30 | — | — | US | claimed |
| CN-118055923-A | Benzodiazepine derivatives as positive allosteric modulators of the GABAA γ1 receptor | 豪夫迈·罗氏有限公司 | 2024-05-17 | — | — | CN | claimed |
| CN-118019745-A | Cyclohepta-thieno-diazapine derivatives as positive allosteric modulators of the GABAA gamma 1 receptor | 豪夫迈·罗氏有限公司 | 2024-05-10 | — | — | CN | claimed |
| CN-118019742-A | Novel benzodiazepine derivatives as GABA Aγ1 PAM | 豪夫迈·罗氏有限公司 | 2024-05-10 | — | — | CN | claimed |
| CN-117957227-A | Pyridodiazepine derivatives as GABA Aγ1 PAM | 豪夫迈·罗氏有限公司 | 2024-04-30 | — | — | CN | claimed |
| EP-4355741-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | Biotheryx, Inc. (US) | 2024-04-24 | — | — | EP | claimed |
| CN-116648250-A | Novel quinazoline derivatives as SOS1 inhibitors and uses thereof | 韩美药品株式会社 | 2023-08-25 | — | — | CN | claimed |
| WO-2019243550-A1 | THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE | UCB Biopharma SRL (BE) | 2019-12-26 | — | — | WO | claimed |
| EP-3105216-B1 | PYRAZINE MODULATORS OF GPR6 | TAKEDA PHARMACEUTICALS CO (JP) | 2018-10-10 | — | — | EP | claimed |
| EP-2933247-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2018-08-29 | — | — | EP | claimed |
| EP-3004086-A1 | SUBSTITUTED BENZOXAZOLES | Bayer Pharma Aktiengesellschaft (DE) | 2016-04-13 | — | — | EP | claimed |
| WO-2014195230-A1 | SUBSTITUTED BENZOXAZOLES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-12-11 | — | — | WO | claimed |
| EP-1562925-B1 | PHENYLALANINE DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO INC (US) | 2007-01-03 | — | — | EP | claimed |
| US-7157490-B2 | Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK & CO., INC. (US) | 2007-01-02 | — | — | US | claimed |
| US-20050222140-A1 | Phenylalanine derivatives as depeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME LLC | 2005-10-06 | — | — | US | claimed |
| EP-1562925-A1 | PHENYLALANINE DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | Merck & Co., Inc. (US) | 2005-08-17 | — | — | EP | claimed |
| WO-2004043940-A1 | PHENYLALANINE DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO., INC. (US) | 2004-05-27 | — | — | WO | claimed |